<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230712230548&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu 80 03KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium= rss&amp;fc =20230708114047<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230712230548&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 13 日星期四 03:05:49 +0000</lastbuilddate><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>长 QT 综合征患者晕厥触发类型与后续危及生命事件的风险之间的关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37436769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项研究中，LQTS 患者的触发特异性晕厥与后续 LTE 的不同风险和对 β 受体阻滞剂治疗的反应相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 12 日。doi：10.1001/jamacardio.2023.1951。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：晕厥是先天性长 QT 综合征 (LQTS) 患者后续危及生命事件 (LTE) 的最有力预测因子。不同的晕厥触发因素是否与后续 LTE 风险的差异相关尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估 LQT 1 至 3 型 (LQT1-3) 患者中肾上腺素能 (AD) 和非肾上腺素能 (non-AD) 触发的晕厥事件与后续 LTE 风险之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这项回顾性队列研究包括来自 5 个国际 LQTS 注册中心（纽约州罗彻斯特；明尼苏达州罗彻斯特的梅奥诊所；以色列、荷兰和日本）的数据。研究人群包括 2938 名经基因证实患有 LQTS 的患者。 LQT1、LQT2 或 LQT3 源于单一 LQTS 致病变异。患者于 1979 年 7 月至 2021 年 7 月期间入组。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：AD 和非 AD 触发引起的晕厥。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：主要终点是首次发生 LTE。使用多变量 Cox 回归来确定 AD 或非 AD 触发的晕厥与基因型后续 LTE 风险之间的关联。在服用β受体阻滞剂的患者。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共纳入了 2938 名患者（入组时的平均 [SD] 年龄为 29 [7] 岁；1645 名女性 [56%]）。在 1331 名 LQT1 患者中，365 名（27%）发生首次晕厥，并且主要由 AD 触发因素诱发 (243 [67%])。晕厥先于 43 次后续 LTE (68%)。与 AD 触发因素相关的晕厥发作与后续 LTE 的最高风险相关（风险比 [HR]，7.61；95% CI P &lt; .001)，而非 AD 触发因素导致的晕厥事件相关风险在统计上不显着 (HR, 1.50; 95% CI, 0.21-4.77; P = .97)。LQT2，首次晕厥发生于 283 例 ( 26%），分别与 106 例（37%）和 177 例（63%）的 AD 和非 AD 触发相关。晕厥先于 55 次 LTE（56%）。非 AD 触发的晕厥与超过 3 次相关。随后 LTE 的风险增加一倍（HR，3.07；95% CI，1.66-5.67；P ≤ .001；HR，3.45，95% CI，1.96-6.06；P ≤ .001）。相比之下，在 501在 LQT3 患者中，7 名 (12%) 患者在 LTE 之前发生过晕厥发作。在 LQT1 和 LQT2 患者中，晕厥事件后使用 β 受体阻滞剂治疗可显着降低随后发生 LTE 的风险。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项研究中，LQTS 患者的触发特异性晕厥与后续 LTE 的不同风险和对 β 受体阻滞剂治疗的反应相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37436769/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37436769</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.1951>10.1001/jamacardio.2023.1951</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37436769</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>阿尔瓦·尤尼斯</dc:creator><dc:creator>J·马丁·博斯</dc:creator><dc:creator>沃伊切赫·扎雷巴</dc:creator><dc:creator>穆罕默德·K·阿克塔斯</dc:creator><dc:creator>阿瑟·王尔德</dc:creator><dc:creator>查迪·塔巴贾</dc:creator><dc:creator>克里斯托弗·博杜里安</dc:creator><dc:creator>凯瑟琳·E·托伯特</dc:creator><dc:creator>斯科特·麦克尼特</dc:creator><dc:creator>布罗尼斯拉娃·波隆斯基</dc:creator><dc:creator>清水涉</dc:creator><dc:creator>——迈克尔·J·阿克曼</dc:creator><dc:creator>伊兰·戈登伯格</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>长 QT 综合征患者晕厥触发类型与后续危及生命事件的风险之间的关联</dc:title><dc:identifier>下午：37436769</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1951</dc:identifier></item><item><title>无临床心力衰竭答复人群的连续 N 端 B 型利钠肽测量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37436758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 12 日。doi：10.1001/jamacardio.2023.1965。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37436758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37436758</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.1965>10.1001/jamacardio.2023.1965</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37436758</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>马哈茂德·阿尔·里法伊</dc:creator><dc:creator>贾晓明</dc:creator><dc:creator>维杰·南比更多</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>无临床心力衰竭答复人群的连续 N 端 B 型利钠肽测量</dc:title><dc:identifier>下午：37436758</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1965</dc:identifier></item><item><title>无临床心力衰竭人群的连续 N 端 Pro-B 型利尿钠肽测量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37436731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 12 日。doi：10.1001/jamacardio.2023.1962。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37436731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37436731</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.1962>10.1001/jamacardio.2023.1962</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37436731</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>戴哲浩</dc:creator><dc:creator>大出幸子</dc:creator><dc:date>2023-07-12</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>无临床心力衰竭人群的连续 N 端 Pro-B 型利尿钠肽测量</dc:title><dc:identifier>下午：37436731</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.1962</dc:identifier></item><item><title> SAPIS 队列中 8973 名参与者的肠道内链球菌物种丰度与亚临床冠状动脉粥样硬化有关</title><link/>https://pubmed.ncbi.nlm.nih.gov/37435755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论：这项研究提供了肠道微生物群组成的证据，其特征是口腔中常见的链球菌属和其他物种的丰度增加与冠状动脉粥样硬化和全身炎症标志物之间的关联。需要进一步的纵向和实验研究来探索其潜在影响。动脉粥样硬化形成中的细菌成分。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 12 日。doi：10.1161/CIRCULATIONAHA.123.063914。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：肠道微生物群与动脉粥样硬化疾病有关，但它们与亚临床冠状动脉粥样硬化的关系尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对 8973 名无明显动脉粥样硬化疾病的参与者（50 至 65 岁）进行了一项基于人群的 SAPIS（瑞典心肺生物图像研究）的横断面研究。使用冠状动脉钙评分和冠状动脉计算机断层扫描来测量冠状动脉粥样硬化血管造影。通过粪便鸟枪法宏基因组测序评估肠道微生物群的丰度和功能潜力，并通过针对心血管危险因素调整的多变量回归模型评估与冠状动脉粥样硬化的关联。评估相关物种与炎症标志物、代谢物和相应物种的关联在唾液中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：研究样本的平均年龄为 57.4 岁，其中 53.7% 为女性。40.3% 的人检测到冠状动脉钙化，5.4% 的人至少有 1 处狭窄且闭塞 >;50%。64 个物种与冠状动脉相关。动脉钙化评分独立于心血管危险因素，观察到<i>咽峡炎链球菌</i>和<i>口腔链球菌</i><i>口腔</i><i>亚</i>种的关联性最强（ <i>P</i> &lt;1×10 <sup>-5</sup> ）。在基于冠状动脉计算机断层扫描血管造影的测量中，关联性很大程度上相似。，19个物种，包括链球菌和口腔中常见的其他菌种与高敏 C 反应蛋白血浆浓度相关，16 种与中性粒细胞计数相关。血浆吲哚丙酸与血浆次级胆汁酸和咪唑丙酸呈正相关。5 个菌种，包括 3 种在马尔默后代牙科研究中，链球菌与唾液中的同一物种相关，并且与较差的牙齿健康状况相关。异化硝酸盐还原、厌氧脂肪酸 β-氧化和氨基酸降解的微生物功能潜力与冠状动脉钙评分相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究提供了肠道微生物群组成的证据，其特征是口腔中常见的<i>链球菌</i>属和其他物种的丰度增加与冠状动脉粥样硬化和全身炎症标志物之间的关联。需要进一步的纵向和实验研究来探索其潜在影响。动脉粥样硬化形成中的细菌成分。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37435755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37435755</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063914>10.1161/CIRCULATIONAHA.123.063914</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37435755</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>塞尔吉·萨约尔斯-拜塞拉斯</dc:creator><dc:creator>科恩·F·德克斯</dc:creator><dc:creator>加布里埃尔·巴尔丹齐</dc:creator><dc:creator>丹尼尔·詹森</dc:creator><dc:creator>乌尔夫·哈马尔</dc:creator><dc:creator>林怡婷</dc:creator><dc:creator>沙夫卡特·艾哈迈德</dc:creator><dc:creator>吴庭艳</dc:creator><dc:creator>乔治斯·瓦罗西斯</dc:creator><dc:creator>萨拉·皮塔</dc:creator><dc:creator>妮妮·尼尔森</dc:creator><dc:creator>阿伦·埃克伦德</dc:creator><dc:creator>雅各布·霍尔姆</dc:creator><dc:creator>H 比约恩·尼尔森</dc:creator><dc:creator>乌尔丽卡·埃里克森</dc:creator><dc:creator>路易丝·布伦克沃尔</dc:creator><dc:creator>菲利普·奥托森</dc:creator><dc:creator>安娜·拉尔森</dc:creator><dc:creator>丹·埃里克森</dc:creator><dc:creator>比约恩·克林格</dc:creator><dc:creator>彼得·尼尔森</dc:creator><dc:creator>安德烈·马利诺夫斯基</dc:creator><dc:creator>拉斯·林德</dc:creator><dc:creator>戈兰·伯格斯特罗姆</dc:creator><dc:creator>约翰·桑德斯特罗姆</dc:creator><dc:creator>约翰·阿恩勒夫</dc:creator><dc:creator>冈纳·恩斯特罗姆</dc:creator><dc:creator>J·古斯塔夫·史密斯</dc:creator><dc:creator>马朱·奥尔霍-梅兰德</dc:creator><dc:creator>托芙·福尔</dc:creator><dc:date>2023-07-12</dc:date><dc:source>循环</dc:source><dc:title>SAPIS 队列中 8973 名参与者的肠道内链球菌物种丰度与亚临床冠状动脉粥样硬化有关</dc:title><dc:identifier>下午：37435755</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.063914</dc:identifier></item><item><title> CTLA-4 通路在巨细胞动脉炎中发挥作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37435729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论：我们强调了 CTLA-4 免疫检查点在 GCA 中的重要作用，这为靶向该通路提供了强有力的理由。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 12 日。doi：10.1161/CIRCRESAHA.122.322330。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：巨细胞动脉炎（GCA）引起主动脉及其分支严重炎症，以效应T细胞强烈浸润为特征，免疫检查点在GCA发病机制中的作用尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：首先利用世界卫生组织国际药物警戒数据库VigiBase评估GCA发生与免疫检查点抑制剂治疗之间的关系，然后利用免疫组化、免疫荧光、对 GCA 患者和适当对照的外周血单核细胞和主动脉组织进行转录组学和流式细胞术。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：使用 VigiBase，我们将 GCA 确定为与抗 CTLA-4（细胞毒性 T 淋巴细胞相关蛋白 4）治疗相关的显着免疫相关不良事件，但与抗 PD-1/PD-L1 治疗无关。通过鉴定与对照相比，GCA 患者血液和主动脉中存在的 CTLA-4 衍生基因途径和 CD4 <sup>+</sup> T 细胞（特别是调节性 T 细胞）中蛋白质的失调，来研究 GCA 中的 CTLA-4 途径。与对照组相比， <sup>GCA</sup>的血液和主动脉<sup>中的</sup>丰富性和激活/抑制性较低，但与对照组相比，它们仍然特异性上调 CTLA-4.-4 (ipilimumab) 介导的体外消耗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们强调了 CTLA-4 免疫检查点在 GCA 中的重要作用，这为靶向该通路提供了强有力的理由。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37435729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37435729</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322330>10.1161/CIRCRESAHA.122.322330</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37435729</guid><pubDate> Wed, 12 Jul 2023 06:00:00 -0400</pubDate><dc:creator>保罗·雷格尼尔</dc:creator><dc:creator>亚历山大·勒琼库尔</dc:creator><dc:creator>安娜·马切耶夫斯基-杜瓦尔</dc:creator><dc:creator>纪尧姆·达拉斯-耶兹</dc:creator><dc:creator>查尔斯·多拉迪尔</dc:creator><dc:creator>沃特·C·梅杰斯</dc:creator><dc:creator>丽莎·巴斯塔拉奇</dc:creator><dc:creator>皮埃尔·富雷</dc:creator><dc:creator>帕特里克·布鲁内瓦尔</dc:creator><dc:creator>弗洛丽安·阿巴雷塔兹</dc:creator><dc:creator>西莉亚·萨耶塔</dc:creator><dc:creator>安娜·马尔克斯</dc:creator><dc:creator>米歇尔·罗森茨瓦格</dc:creator><dc:creator>大卫·克拉兹曼</dc:creator><dc:creator>帕特里斯·卡库布</dc:creator><dc:creator>贾维德·J·莫斯莱希</dc:creator><dc:creator>乔·埃利·塞勒姆</dc:creator><dc:creator>大卫·萨杜恩</dc:creator><dc:date>2023-07-12</dc:date><dc:source>流通研究</dc:source><dc:title>CTLA-4 通路在巨细胞动脉炎中发挥作用</dc:title><dc:identifier>下午：37435729</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322330</dc:identifier></item><item><title>心血管疾病患者的残余环境风险：一个被忽视的范例</title><link/>https://pubmed.ncbi.nlm.nih.gov/37431798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 11​​:ehad412.doi: 10.1093/eurheartj/ehad412. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37431798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37431798</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad412>10.1093/eurheartj/ehad412</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37431798</guid><pubDate> Tue, 11 Jul 2023 06:00:00 -0400</pubDate><dc:creator>萨德尔·金迪</dc:creator><dc:creator>弗朗西斯科帕内尼</dc:creator><dc:creator>——罗伯特·D·布鲁克</dc:creator><dc:creator>桑杰·拉贾戈帕兰 (Sanjay Rajagopalan)</dc:creator><dc:date> 2023-07-11</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心血管疾病患者的残余环境风险：一个被忽视的范例</dc:title><dc:identifier>下午：37431798</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad412</dc:identifier></item><item><title>肥厚型心肌病的种族、血缘关系和遗传结构</title><link/>https://pubmed.ncbi.nlm.nih.gov/37431535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论：研究近亲群体揭示了与基因检测相关的新见解以及我们对 HCM 遗传结构的理解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 11​​:ehad372.doi: 10.1093/eurheartj/ehad372. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：肥厚型心肌病 (HCM) 的特点是表型异质性，部分原因是导致疾病的遗传变异的多样性。对这些变异的准确解释构成了诊断和实施精准医疗的重大挑战，特别是在研究不足的人群中。使用血统匹配的病例和对照，研究具有高度血缘关系的北非人群中 HCM 的遗传结构。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：潜在的埃及患者 (n = 514) 和对照 (n = 400) 接受了临床表型分析和基因检测。根据标准临床指南对 13 个经过验证的 HCM 基因中的罕见变异进行了分类，并与大多数欧洲人的前瞻性 HCM 队列进行了比较祖先（n = 684）。在埃及患者中观察到纯合变异的患病率较高（4.1% vs. 0.1%，P = 2 × 10-7），次要 HCM 基因 MYL2、MYL3 和 CSRP3 中的变异更有可能与主要基因相比，以纯合性存在，表明这些变异在杂合性中的渗透性较低。在 2.1% 的患者中检测到隐性 HCM 基因 TRIM63 的双等位基因变异（比欧洲患者高出五倍），强调了隐性遗传在最后，与欧洲人相比，埃及 HCM 患者的罕见变异不太可能被归类为（可能）致病性（40.8% vs. 61.6%，P = 1.6 × 10-5），因为埃及 HCM 患者中中东人群的代表性不足。在采用此处介绍的新血统匹配对照的方法后，这一比例增加到 53.3%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：研究近亲群体揭示了与基因检测相关的新见解以及我们对 HCM 遗传结构的理解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37431535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37431535</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad372>10.1093/eurheartj/ehad372</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37431535</guid><pubDate> Tue, 11 Jul 2023 06:00:00 -0400</pubDate><dc:creator>莫娜·阿卢巴更多</dc:creator><dc:creator>罗迪·沃尔什</dc:creator><dc:creator>阿拉·阿菲菲</dc:creator><dc:creator>穆罕默德·霍斯尼</dc:creator><dc:creator>萨拉·哈拉瓦</dc:creator><dc:creator>阿雅·加拉尔</dc:creator><dc:creator>玛丽雅姆·法蒂</dc:creator><dc:creator>潘塔齐斯一世西奥托基斯</dc:creator><dc:creator>艾哈迈德·博拉伊</dc:creator><dc:creator>阿曼尼·埃利西</dc:creator><dc:creator>——雷切尔·巴肯</dc:creator><dc:creator>里莎·戈文德更多</dc:creator><dc:creator>尼古拉·惠芬</dc:creator><dc:creator>谢哈布·安维尔</dc:creator><dc:creator>艾哈迈德·埃尔·古因迪</dc:creator><dc:creator>詹姆斯·S·威尔</dc:creator><dc:creator>保罗·JR·巴顿</dc:creator><dc:creator>马格迪·雅各布</dc:creator><dc:creator>亚斯敏·阿吉布</dc:creator><dc:date>2023-07-11</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肥厚型心肌病的种族、血缘关系和遗传结构</dc:title><dc:identifier>下午：37431535</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad372</dc:identifier></item><item><title>勘误表：癌症诊断后吸烟习惯的改变：对心血管风险的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37431148/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 11​​:ehad443.doi: 10.1093/eurheartj/ehad443. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37431148/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37431148</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad443>10.1093/eurheartj/ehad443</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37431148</guid><pubDate> Tue, 11 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-11</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>勘误表：癌症诊断后吸烟习惯的改变：对心血管风险的影响</dc:title><dc:identifier>下午：37431148</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad443</dc:identifier></item><item><title>更正：儿童心肌病的治疗策略：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):e3.doi: 10.1161/CIR.0000000000001170. Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428834</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001170>10.1161/CIR.0000000000001170</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428834</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>更正：儿童心肌病的治疗策略：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37428834</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001170</dc:identifier></item><item><title> PCSK9 书中的新章节：用大环肽口服抑制 PCSK9 与 LDL 受体的结合</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):159-161. doi: 10.1161/CIRCULATIONAHA.123.06540​​7. Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428833</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065407>10.1161/CIRCULATIONAHA.123.06540​​7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428833</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator>乌尔夫·兰德梅塞尔</dc:creator><dc:creator>乌米达洪·马赫穆多娃</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>PCSK9 书中的新章节：用大环肽口服抑制 PCSK9 与 LDL 受体的结合</dc:title><dc:identifier>下午：37428833</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.06540​​7</dc:identifier></item><item><title> Teng 等人关于文章“直接重编程改善心脏功能并逆转慢性心肌梗死的纤维化”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):170-171。doi: 10.1161/CIRCULATIONAHA.123.064097。Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428832</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064097>10.1161/CIRCULATIONAHA.123.064097</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428832</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator>滕振清</dc:creator><dc:creator>向马</dc:creator><dc:creator>马一桐</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>Teng 等人关于文章“直接重编程改善心脏功能并逆转慢性心肌梗死的纤维化”的信函</dc:title><dc:identifier>下午：37428832</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064097</dc:identifier></item><item><title>肥厚型心肌病中心肌脑啡肽酶升高</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):167-169. doi: 10.1161/CIRCULATIONAHA.123.064153. Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428831</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064153>10.1161/CirculationAHA.123.064153</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428831</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——大卫·W·J·阿姆斯特朗</dc:creator><dc:creator>兰斯·莱利</dc:creator><dc:creator>颜如素</dc:creator><dc:creator>阿什什·沙阿</dc:creator><dc:creator>塔里克·阿布西</dc:creator><dc:creator>Deepak K Gupta更多</dc:creator><dc:creator>奎因·S·威尔斯</dc:creator><dc:creator>D·马歇尔·布林克利</dc:creator><dc:creator>——林恩·W·史蒂文森</dc:creator><dc:creator>W大卫·梅里曼</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>肥厚型心肌病中心肌脑啡肽酶升高</dc:title><dc:identifier>下午：37428831</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064153</dc:identifier></item><item><title> &lt;em>;流通&lt;/em>;系列期刊的亮点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):162-166. doi: 10.1161/CIRCULATIONAHA.123.065701. Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428830</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065701>10.1161/CIRCULATIONAHA.123.065701</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428830</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>&lt;em>;流通&lt;/em>;系列期刊的亮点</dc:title><dc:identifier>下午：37428830</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065701</dc:identifier></item><item><title> Sadahiro 等人对有关文章“直接重编程改善心脏功能并逆转慢性心肌梗塞中的纤维化”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37428829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 7 月 11 日；148(2):172-173. doi: 10.1161/CIRCULATIONAHA.123.065132. Epub 2023 年 7 月 10 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37428829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37428829</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065132>10.1161/循环AHA.123.065132</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37428829</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator>武太郎贞宏</dc:creator><dc:creator>谷英德</dc:creator><dc:creator>家田正树</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>Sadahiro 等人对有关文章“直接重编程改善心脏功能并逆转慢性心肌梗塞中的纤维化”的信件的回应</dc:title><dc:identifier>下午：37428829</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065132</dc:identifier></item><item><title>为治疗心血管疾病的临床医生提供基于价值的支付：美国心脏协会的政策声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37427456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>临床医生付费正在从按服务付费过渡到基于价值的付费，报销与医疗保健质量和成本挂钩。这一点在很大程度上尚未得到满足。本政策声明回顾了基于价值的付费的当前状态，并提供了推荐的最佳实践未来的设计和实施。政策声明分为几个部分，详细介绍了……的不同方面。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 10 日。doi：10.1161/CIR.0000000000001143。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床医生付费正在从按服务付费过渡到基于价值的付费，报销与医疗保健质量和成本挂钩。本政策声明回顾了基于价值的付费的当前状态，并为未来的设计和实施提供了建议的最佳实践。政策声明分为几个部分，详细介绍了基于价值的支付的不同方面：(1) 关键项目设计特征（患者群体、质量衡量、成本衡量和风险调整），(2) 公平在设计和评估过程中的作用， (3) 支付调整，(4) 计划实施和评估。每个部分都包括为未来计划设计推荐的最佳实践。政策声明强调了成功基于价值的支付的 4 个关键主题。首先，计划应仔细权衡之间的激励措施其次，扩大基于价值的支付应成为改善公平性的工具，公平性是医疗质量的核心，应成为医疗保健质量的重点。项目设计和评估。第三，基于价值的支付应继续从服务收费转向更灵活的资助，使临床医生能够将资源集中在最能帮助患者的干预措施上。最后，成功的项目应该找到方法来引导临床医生的内在这些原则应该指导临床医生基于价值的支付模式的未来发展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37427456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37427456</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001143>10.1161/CIR.0000000000001143</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37427456</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator>亚历山大·桑杜</dc:creator><dc:creator>保罗·A·海登赖希</dc:creator><dc:creator>威廉·博登</dc:creator><dc:creator>史蒂文·农夫</dc:creator><dc:creator>P 迈克尔·何</dc:creator><dc:creator>格默里斯·哈蒙德</dc:creator><dc:creator>詹妮·C·约翰逊</dc:creator><dc:creator>Rishi K Wadhera更多</dc:creator><dc:creator>杰森·H·瓦斯菲</dc:creator><dc:creator>凯茜·比加</dc:creator><dc:creator>埃德温·高桥</dc:creator><dc:creator>Khamal D Misra更多</dc:creator><dc:creator>凯伦·E·乔恩特·马多克斯</dc:creator><dc:creator>美国心脏协会倡导协调委员会</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>为治疗心血管疾病的临床医生提供基于价值的支付：美国心脏协会的政策声明</dc:title><dc:identifier>下午：37427456</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001143</dc:identifier></item><item><title>组织细胞外囊泡的多组学鉴定了动脉粥样硬化和钙化性主动脉瓣狭窄的独特调节剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37427430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论：第一个针对人类颈动脉斑块和钙化主动脉瓣的比较蛋白质组学研究确定了动脉粥样硬化与主动脉瓣狭窄的独特驱动因素，并暗示 EVs 与晚期心血管钙化有关。我们描述了一种囊泡组学策略，用于分离、纯化和研究来自动脉粥样硬化和主动脉瓣狭窄的蛋白质和 RNA 货物。 EVs 被捕获在纤维钙化组织中。通过网络方法整合囊泡蛋白质组学和转录组学揭示了组织 EVs 在……中的新作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 10 日。doi：10.1161/CIRCULATIONAHA.122.063402。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：不到 50% 的主动脉瓣钙化患者伴有动脉粥样硬化，这意味着不同的发病机制。虽然循环细胞外囊泡 (EV) 是心血管疾病的生物标志物，但组织截留的 EV 与早期矿化有关，但它们的负载、功能，并且对疾病的贡献仍然未知。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对人颈动脉内膜切除标本 (n=16) 和狭窄主动脉瓣 (n=18) 进行疾病分期特异性蛋白质组学。从人颈动脉中分离组织 EV（正常，n=6；患病，n=4）通过酶消化、（超）离心和通过蛋白质组学、CD63-免疫金电子显微镜和纳米颗粒跟踪分析验证的 15 级分密度梯度，对主动脉瓣（正常，n=6；患病，n=4）进行分析。对组织 EV 进行了小 RNA 测序。TargetScan 识别了 microRNA 目标。通路网络分析了优先基因，以在原代人颈动脉平滑肌细胞和主动脉瓣间质细胞中进行验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：疾病进展导致颈动脉斑块和钙化主动脉瓣蛋白质组（2318 个蛋白质）显着趋同（ <i>P</i> &lt;0.0001）。每个组织还保留了差异富集蛋白质的独特子集（斑块中 381 个；瓣膜中 226 个；q&lt;0.05）两种组织中受疾病调节的蛋白质中的囊泡基因本体术语增加了 2.9 倍（ <i>P</i> &lt;0.0001）。蛋白质组学在组织消化部分中鉴定出了 22 个 EV 标记。动脉和瓣膜 EV 中疾病进展而改变的蛋白质和 microRNA 靶标网络揭示了共享的参与细胞内信号传导和细胞周期调节。囊泡组学鉴定了仅在动脉或瓣膜 EV 中因疾病而差异富集的 773 种蛋白质和 80 种 microRNA（q&lt;0.05）；多组学整合发现了与颈动脉中促钙化 Notch 和 Wnt 信号传导相关的组织特异性 EV 货物。分别敲低人颈动脉平滑肌细胞中的组织特异性 EV 货物<i>FGFR2</i> 、 <i>PPP2CA</i>和<i>ADAM17</i>以及人主动脉瓣膜间质细胞中的<i>WNT5A</i> 、 <i>APP</i>和<i>APC</i>显着调节钙化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：第一个针对人类颈动脉斑块和钙化主动脉瓣的比较蛋白质组学研究确定了动脉粥样硬化与主动脉瓣狭窄的独特驱动因素，并暗示 EVs 与晚期心血管钙化有关。我们描述了一种囊泡组学策略，用于分离、纯化和研究来自动脉粥样硬化和主动脉瓣狭窄的蛋白质和 RNA 货物。纤维钙化组织中的 EVs。通过网络方法整合囊泡蛋白质组学和转录组学揭示了组织 EVs 在调节心血管疾病中的新作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37427430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37427430</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063402>10.1161/CIRCULATIONAHA.122.063402</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37427430</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator>马克·C·布拉瑟</dc:creator><dc:creator>法布里奇奥·布弗罗</dc:creator><dc:creator>阿尔达·哈鲁</dc:creator><dc:creator>曼迪·E·特纳</dc:creator><dc:creator>弗洛里安·施洛特</dc:creator><dc:creator>东英行</dc:creator><dc:creator>洛雷娜·潘塔诺</dc:creator><dc:creator>卡桑德拉·L·克利夫特</dc:creator><dc:creator>路易斯·萨迪克</dc:creator><dc:creator>萨曼莎·阿特金斯</dc:creator><dc:creator>马克西米利安·罗杰斯</dc:creator><dc:creator>陈范</dc:creator><dc:creator>阿梅莉·弗罗曼</dc:creator><dc:creator>尤金尼娅·施瓦茨</dc:creator><dc:creator>加琳娜·K·苏霍娃</dc:creator><dc:creator>西尔维娅·蒙蒂科内</dc:creator><dc:creator>乔瓦尼·卡穆西</dc:creator><dc:creator>西蒙·罗布森</dc:creator><dc:creator>西蒙·C·博迪</dc:creator><dc:creator>约亨·D·米尔施莱格尔</dc:creator><dc:creator>萨沙·辛格</dc:creator><dc:creator>相川正德</dc:creator><dc:creator>艾琳娜·相川</dc:creator><dc:date>2023-07-10</dc:date><dc:source>循环</dc:source><dc:title>组织细胞外囊泡的多组学鉴定了动脉粥样硬化和钙化性主动脉瓣狭窄的独特调节剂</dc:title><dc:identifier>下午：37427430</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063402</dc:identifier></item><item><title>通过单细胞 RNA 测序评估心脏非编码转录组，鉴定出 FIXER，一种保守的促纤维化长非编码 RNA</title><link/> https://pubmed.ncbi.nlm.nih.gov/37427428/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230712230548&amp;v=2.17.9.post6+86293ac<description>结论：我们的结果表明，lncRNA 表达足以识别构成哺乳动物心脏的各种细胞类型。重点关注心脏成纤维细胞及其衍生物，我们鉴定了肌成纤维细胞中独特表达的 lncRNA。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 10 日。doi：10.1161/CIRCULATIONAHA.122.062601。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心脏成纤维细胞在心脏中起着至关重要的作用，特别是在受损的心肌中，成纤维细胞分化为肌成纤维细胞，导致疤痕形成和间质纤维化。纤维化与心脏功能障碍和衰竭相关，缺乏肌成纤维细胞特异性标记物阻碍了其发展靶向治疗。在这种情况下，大多数非编码基因组被转录为长非编码 RNA (lncRNA)。许多 lncRNA 在心血管系统中具有关键功能。-比蛋白质编码基因具有特异性，支持它们作为心血管系统关键决定因素的重要性细胞身份。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this study, we evaluated the value of the lncRNA transcriptome in very deep single-cell RNA sequencing. We profiled the lncRNA transcriptome in cardiac nonmyocyte cells after infarction and probed heterogeneity in the fibroblast and myofibroblast populations. In addition, we searched for subpopulation-specific markers that can constitute novel targets in therapy for heart disease. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We demonstrated that cardiac cell identity can be defined by the sole expression of lncRNAs in single-cell experiments. In this analysis, we identified lncRNAs enriched in relevant myofibroblast subpopulations. Selecting 1 candidate we named <i>FIXER</i> (fibrogenic <i>LOX</i> -locus enhancer RNA), we showed that its silencing limits fibrosis and improves heart function after infarction. <i>FIXER</i> mechanistically associates with CBX4, an E3 SUMO (small ubiquitin-like modifier) protein ligase and a transcription factor, target CBX4 to the promoter of the transcription factor RUNX1 to regulate its expression and thereby the whole fibrogenic gene program. <i>FIXER</i> is conserved in humans, supporting its translational value. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Our results demonstrated that lncRNA expression is sufficient to identify the various cell types composing the mammalian heart. Focusing on cardiac fibroblasts and their derivatives, we identified lncRNAs uniquely expressed in myofibroblasts. In particular, the lncRNA <i>FIXER</i> represents a novel therapeutic target for cardiac fibrosis.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37427428/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37427428</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062601>10.1161/CIRCULATIONAHA.122.062601</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37427428</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Parisa Aghagolzadeh</dc:creator><dc:creator> Isabelle Plaisance</dc:creator><dc:creator> Riccardo Bernasconi</dc:creator><dc:creator> Thomas A Treibel</dc:creator><dc:creator> Carlos Pulido Quetglas</dc:creator><dc:creator> Tania Wyss</dc:creator><dc:creator> Leonore Wigger</dc:creator><dc:creator> Mohamed Nemir</dc:creator><dc:creator> Alexandre Sarre</dc:creator><dc:creator> Panagiotis Chouvardas</dc:creator><dc:creator> Rory Johnson</dc:creator><dc:creator> Arantxa González</dc:creator><dc:creator> Thierry Pedrazzini</dc:creator><dc:date> 2023-07-10</dc:date><dc:source> Circulation</dc:source><dc:title> Assessment of the Cardiac Noncoding Transcriptome by Single-Cell RNA Sequencing Identifies &lt;em>;FIXER&lt;/em>;, a Conserved Profibrogenic Long Noncoding RNA</dc:title><dc:identifier> pmid:37427428</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.062601</dc:identifier></item><item><title> Person-Centered Models for Cardiovascular Care: A Review of the Evidence: A Scientific Statement From the American Heart Association</title><link/> https://pubmed.ncbi.nlm.nih.gov/37427418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230712230548&amp;v=2.17.9.post6+86293ac<description> Cardiovascular disease remains the leading cause of death and disability in the United States and globally. Disease burden continues to escalate despite technological advances associated with improved life expectancy and quality of life. As a result, longer life is associated with multiple chronic cardiovascular conditions. Clinical guidelines provide recommendations without considering prevalent scenarios of multimorbidity and health system complexities that affect practical adoption. The... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Jul 10. doi: 10.1161/CIR.0000000000001141. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Cardiovascular disease remains the leading cause of death and disability in the United States and globally. Disease burden continues to escalate despite technological advances associated with improved life expectancy and quality of life. As a result, longer life is associated with multiple chronic cardiovascular conditions. Clinical guidelines provide recommendations without considering prevalent scenarios of multimorbidity and health system complexities that affect practical adoption. The diversity of personal preferences, cultures, and lifestyles that make up one&#39;s social and environmental context is often overlooked in ongoing care planning for symptom management and health behavior support, hindering adoption and compromising patient outcomes, particularly in groups at high risk. The purpose of this scientific statement was to describe the characteristics and reported outcomes in existing person-centered care delivery models for selected cardiovascular conditions. We conducted a scoping review using Ovid MEDLINE, Embase.com, Web of Science, CINAHL Complete, Cochrane Central Register of Controlled Trials through Ovid, and ClinicalTrials.gov from 2010 to 2022. A range of study designs with a defined aim to systematically evaluate care delivery models for selected cardiovascular conditions were included. Models were selected on the basis of their stated use of evidence-based guidelines, clinical decision support tools, systematic evaluation processes, and inclusion of the patient&#39;s perspective in defining the plan of care. Findings reflected variation in methodological approach, outcome measures, and care processes used across models. Evidence to support optimal care delivery models remains limited by inconsistencies in approach, variation in reimbursement, and inability of health systems to meet the needs of patients with chronic, complex cardiovascular conditions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37427418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37427418</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001141>10.1161/CIR.0000000000001141</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37427418</guid><pubDate> Mon, 10 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Laura P Rossi</dc:creator><dc:creator> Bradi B Granger</dc:creator><dc:creator> Jeffrey T Bruckel</dc:creator><dc:creator> Deborah L Crabbe</dc:creator><dc:creator> Lucinda J Graven</dc:creator><dc:creator> Kimberly S Newlin</dc:creator><dc:creator> Megan M Streur</dc:creator><dc:creator> Maya K Vadiveloo</dc:creator><dc:creator> Benita Jeanne Walton-Moss</dc:creator><dc:creator> Bruce A Warden</dc:creator><dc:creator> Annabelle Santos Volgman</dc:creator><dc:creator> Melissa Lydston</dc:creator><dc:creator> American Heart Association Complex Cardiovascular Patient and Family Care Committee of the Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research</dc:creator><dc:date> 2023-07-10</dc:date><dc:source> Circulation</dc:source><dc:title> Person-Centered Models for Cardiovascular Care: A Review of the Evidence: A Scientific Statement From the American Heart Association</dc:title><dc:identifier> pmid:37427418</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001141</dc:identifier></item><item><title> Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies</title><link/> https://pubmed.ncbi.nlm.nih.gov/37421950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230712230548&amp;v=2.17.9.post6+86293ac<description> Synucleinopathies are characterized by the accumulation of α-synuclein (α-Syn) aggregates in the brain. Positron emission tomography (PET) imaging of synucleinopathies requires radiopharmaceuticals that selectively bind α-Syn deposits. We report the identification of a brain permeable and rapid washout PET tracer [^(18)F]-F0502B, which shows high binding affinity for α-Syn, but not for Aβ or Tau fibrils, and preferential binding to α-Syn aggregates in the brain sections. Employing several cycles... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Jun 27:S0092-8674(23)00644-X. doi: 10.1016/j.cell.2023.06.004. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Synucleinopathies are characterized by the accumulation of α-synuclein (α-Syn) aggregates in the brain. Positron emission tomography (PET) imaging of synucleinopathies requires radiopharmaceuticals that selectively bind α-Syn deposits. We report the identification of a brain permeable and rapid washout PET tracer [ <sup>18</sup> F]-F0502B, which shows high binding affinity for α-Syn, but not for Aβ or Tau fibrils, and preferential binding to α-Syn aggregates in the brain sections. Employing several cycles of counter screenings with in vitro fibrils, intraneuronal aggregates, and neurodegenerative disease brain sections from several mice models and human subjects, [ <sup>18</sup> F]-F0502B images α-Syn deposits in the brains of mouse and non-human primate PD models. We further determined the atomic structure of the α-Syn fibril-F0502B complex by cryo-EM and revealed parallel diagonal stacking of F0502B on the fibril surface through an intense noncovalent bonding network via inter-ligand interactions. Therefore, [ <sup>18</sup> F]-F0502B is a promising lead compound for imaging aggregated α-Syn in synucleinopathies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37421950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37421950</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.06.004>10.1016/j.cell.2023.06.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37421950</guid><pubDate> Sat, 08 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Jie Xiang</dc:creator><dc:creator> Youqi Tao</dc:creator><dc:creator> Yiyuan Xia</dc:creator><dc:creator> Shilin Luo</dc:creator><dc:creator> Qinyue Zhao</dc:creator><dc:creator> Bowei Li</dc:creator><dc:creator> Xiaoqian Zhang</dc:creator><dc:creator> Yunpeng Sun</dc:creator><dc:creator> Wencheng Xia</dc:creator><dc:creator> Mingming Zhang</dc:creator><dc:creator> Seong Su Kang</dc:creator><dc:creator> Eun-Hee Ahn</dc:creator><dc:creator> Xia Liu</dc:creator><dc:creator> Fang Xie</dc:creator><dc:creator> Yihui Guan</dc:creator><dc:creator> Jenny J Yang</dc:creator><dc:creator> Lihong Bu</dc:creator><dc:creator> Shengxi Wu</dc:creator><dc:creator> Xiaochuan Wang</dc:creator><dc:creator> Xuebing Cao</dc:creator><dc:creator> Cong Liu</dc:creator><dc:creator> Zhentao Zhang</dc:creator><dc:creator> Dan Li</dc:creator><dc:creator> Keqiang Ye</dc:creator><dc:date> 2023-07-08</dc:date><dc:source> Cell</dc:source><dc:title> Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies</dc:title><dc:identifier> pmid:37421950</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.004</dc:identifier></item><item><title> TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry</title><link/> https://pubmed.ncbi.nlm.nih.gov/37421949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230712230548&amp;v=2.17.9.post6+86293ac<description> SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal transmembrane protein, can serve as an alternative receptor for SARS-CoV-2 entry into angiotensin-converting enzyme 2 (ACE2)-negative cells. Spike substitution E484D increased TMEM106B binding, thereby enhancing TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies blocked SARS-CoV-2 infection,... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Jul 3:S0092-8674(23)00645-1. doi: 10.1016/j.cell.2023.06.005. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells. Here, we show that TMEM106B, a lysosomal transmembrane protein, can serve as an alternative receptor for SARS-CoV-2 entry into angiotensin-converting enzyme 2 (ACE2)-negative cells. Spike substitution E484D increased TMEM106B binding, thereby enhancing TMEM106B-mediated entry. TMEM106B-specific monoclonal antibodies blocked SARS-CoV-2 infection, demonstrating a role of TMEM106B in viral entry. Using X-ray crystallography, cryogenic electron microscopy (cryo-EM), and hydrogen-deuterium exchange mass spectrometry (HDX-MS), we show that the luminal domain (LD) of TMEM106B engages the receptor-binding motif of SARS-CoV-2 spike. Finally, we show that TMEM106B promotes spike-mediated syncytium formation, suggesting a role of TMEM106B in viral fusion. Together, our findings identify an ACE2-independent SARS-CoV-2 infection mechanism that involves cooperative interactions with the receptors heparan sulfate and TMEM106B.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37421949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37421949</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.06.005>10.1016/j.cell.2023.06.005</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37421949</guid><pubDate> Sat, 08 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Jim Baggen</dc:creator><dc:creator> Maarten Jacquemyn</dc:creator><dc:creator> Leentje Persoons</dc:creator><dc:creator> Els Vanstreels</dc:creator><dc:creator> Valerie E Pye</dc:creator><dc:creator> Antoni G Wrobel</dc:creator><dc:creator> Valeria Calvaresi</dc:creator><dc:creator> Stephen R Martin</dc:creator><dc:creator> Chloë Roustan</dc:creator><dc:creator> Nora B Cronin</dc:creator><dc:creator> Eamonn Reading</dc:creator><dc:creator> Hendrik Jan Thibaut</dc:creator><dc:creator> Thomas Vercruysse</dc:creator><dc:creator> Piet Maes</dc:creator><dc:creator> Frederik De Smet</dc:creator><dc:creator> Angie Yee</dc:creator><dc:creator> Toey Nivitchanyong</dc:creator><dc:creator> Marina Roell</dc:creator><dc:creator> Natalia Franco-Hernandez</dc:creator><dc:creator> Herve Rhinn</dc:creator><dc:creator> Alusha Andre Mamchak</dc:creator><dc:creator> Maxime Ah Young-Chapon</dc:creator><dc:creator> Eric Brown</dc:creator><dc:creator> Peter Cherepanov</dc:creator><dc:creator> Dirk Daelemans</dc:creator><dc:date> 2023-07-08</dc:date><dc:source> Cell</dc:source><dc:title> TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry</dc:title><dc:identifier> pmid:37421949</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.005</dc:identifier></item><item><title> Effective membrane tension: A long-range integrator of cellular dynamics</title><link/> https://pubmed.ncbi.nlm.nih.gov/37419084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230712230548&amp;v=2.17.9.post6+86293ac<description> Membrane tension has been proposed to mechanically couple processes along the cell&#39;s boundary. In this issue of Cell, De Belly et al. show that local protrusion or contraction elicit a global membrane tension increase within seconds, whereas tension perturbations that engage only the membrane remain localized. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Jul 6;186(14):2956-2958. doi: 10.1016/j.cell.2023.05.033.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Membrane tension has been proposed to mechanically couple processes along the cell&#39;s boundary. In this issue of Cell, De Belly et al. show that local protrusion or contraction elicit a global membrane tension increase within seconds, whereas tension perturbations that engage only the membrane remain localized.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37419084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230712230548&v=2.17.9.post6+86293ac">37419084</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.05.033>10.1016/j.cell.2023.05.033</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37419084</guid><pubDate> Fri, 07 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Kinneret Keren</dc:creator><dc:date> 2023-07-07</dc:date><dc:source> Cell</dc:source><dc:title> Effective membrane tension: A long-range integrator of cellular dynamics</dc:title><dc:identifier> pmid:37419084</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.05.033</dc:identifier></item></channel></rss>